LeMaitre Vascular (LMAT) Expected to Announce Quarterly Earnings on Wednesday

LeMaitre Vascular (NASDAQ:LMAT) is expected to post its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.67 per share and revenue of $62.9830 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 5:00 PM ET.

LeMaitre Vascular Price Performance

LMAT stock opened at $92.94 on Monday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58. The firm has a 50 day moving average price of $85.54 and a 200-day moving average price of $88.13. LeMaitre Vascular has a 52-week low of $71.42 and a 52-week high of $105.55. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of 40.06, a PEG ratio of 2.06 and a beta of 0.72.

Institutional Trading of LeMaitre Vascular

Institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada raised its holdings in shares of LeMaitre Vascular by 1.5% during the first quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock valued at $9,579,000 after purchasing an additional 1,735 shares during the last quarter. AQR Capital Management LLC raised its stake in LeMaitre Vascular by 36.4% during the 1st quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock valued at $2,339,000 after buying an additional 7,445 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of LeMaitre Vascular by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after buying an additional 539 shares during the period. Millennium Management LLC boosted its stake in shares of LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after buying an additional 115,141 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock worth $22,019,000 after acquiring an additional 55,804 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on LMAT shares. Cantor Fitzgerald reissued a “neutral” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a report on Monday, November 10th. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reissued a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Monday, December 29th. Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Barrington Research reiterated an “outperform” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a research note on Friday. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $100.20.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.